华润医药(03320.HK)3款产品中选药品集中采购
格隆汇1月20日丨华润医药(03320.HK)发布公告,该集团有3款产品分别于中国全国药品集中采购招标或联盟地区药品集中采购中拟中选,分别为铝碳酸镁咀嚼片、阿奇霉素片及盐酸特拉唑嗪片。若后续签订采购合同并实施,将有利于该等产品扩大其市场覆盖和销售,提升市场竞争力,对集团未来经营业绩产生积极的影响。
目前,该集团已与联合采购办公室就该等产品分别签订适用的《全国药品集中采购拟中选品种备忘录》及《联盟地区药品集中采购拟中选品种备忘录》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.